1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Immutep Limited

Immutep Limited

PRRUF
Immutep LimitedUS flagOther OTC
0.05
USD
- -
- -
73.69MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.01
- -
0.02
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.14
-0.11
-0.2
-0.27
-0.04
-0.05
-0.06
-0.03
-0.05
-0.04
-0.04
- -
- -
- -
Free Cash Flow per Basic Share
-0.15
-0.11
-0.05
-0.05
-0.04
- -
- -
- -
- -
-0.05
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.25
0.16
0.12
-0.12
-0.17
-0.12
-0.12
-0.08
0.06
0.07
0.12
- -
- -
- -
Tangible Book Value per Share
0.26
0.18
0.01
0.06
0.04
0.06
0.02
0.04
0.1
0.1
0.14
- -
- -
- -
Basic Weighted Avg Shares
111
126
164
231
214
269
333
411
610
870
892
- -
1,456
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
3
- -
7
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-35,268.63
- -
-444.55
-13,735.17
-201.32
- -
-19,861.21
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
2
2
2
2
2
- -
3
- -
- -
- -
- -
Net Income, GAAP
-15
-13
-32
-62
-9
-13
-18
-13
-30
-32
-40
-43
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-35,426.72
- -
-484.55
-13,123.28
-179.9
- -
-18,906.51
- -
- -
- -
- -
Working Capital
28
22
4
20
13
25
18
28
63
84
125
181
- -
- -
LT Debt
- -
- -
- -
5
6
7
8
9
3
2
1
1
- -
- -
Total Equity
29
23
25
35
27
34
24
33
73
94
136
190
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-47.33
-55.51
-160.23
- -
- -
- -
- -
- -
- -
-62.03
-46.55
-32.14
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
Total Current Assets
- -
174
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Marc Voigt
Full Time Employees
51
Sector
Healthcare
Industry
Biotechnology
Address
Australia Square Sydney NSW Australia 2000
IPO Date
Feb 22, 2012
Website
immutep.com
Similar Companies
Vallon Pharmaceuticals, Inc. (VLON)
Omnimmune Holdings, Inc. (OMMH)
Surrozen, Inc. (SRZNW)
Chimeric Therapeutics Limited (CHMMF)
Prime Medicine, Inc. (PRME)
Aqua Bio Technology ASA (ABT.OL)
Business
Immutep Limited (ASX:IMM; NASDAQ:IMMP; OTC:PRRUF), a late clinical-stage biotechnology company headquartered in Sydney, Australia, and founded in 1987, develops novel Lymphocyte-Activation Gene-3 (LAG-3) related immunotherapies targeting cancer and autoimmune diseases; its diversified portfolio features lead candidate eftilagimod alfa (efti), a first-in-class MHC Class II agonist in pivotal Phase III TACTI-004 (KEYNOTE-F91) trial combined with pembrolizumab and chemotherapy for first-line non-small cell lung cancer across more than 150 global sites in 24 countries, alongside Phase IIb TACTI-003 in head and neck squamous cell carcinoma, Phase II AIPAC-003 in metastatic breast cancer, investigator-initiated trials like EFTISARC-NEO in soft tissue sarcoma which met its primary endpoint of tumor hyalinization, INSIGHT-003 and INSIGHT-005 in various lung and urothelial cancers, IMP761 agonist antibody in Phase I for autoimmune conditions, and licensed assets such as LAG525 to Novartis and collaborations with Merck & Co., GlaxoSmithKline, Pfizer, EOC Pharma, and others. The company operates primarily in Australia, the United States, Germany, and France, serving oncology and autoimmune patient populations through clinical-stage assets focused on immune modulation to enhance anti-tumor responses or suppress dysregulated immunity. Recent developments include positive FDA feedback in August 2025 on late-stage efti paths for head and neck cancer with CPS <1 potentially via accelerated approval, enrollment completion in AIPAC-003 Phase II with data presentation at the 2025 San Antonio Breast Cancer Symposium, primary endpoint achievement and oral presentations for EFTISARC-NEO at ESMO and CTOS 2025, launch of a new investigator-initiated Phase II neoadjuvant trial in HR+/HER2- breast cancer with George Washington University, over 170 patients enrolled in TACTI-004 surpassing futility analysis thresholds, four new patents granted covering efti manufacturing and IMP761/LAG525, appointment of Stephan Winckels as permanent Chief Medical Officer in July 2025, and a strong cash position of A$109.85 million as of September 30, 2025 supporting runway into late 2026.